EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study) (PALABA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03669367 |
Recruitment Status :
Active, not recruiting
First Posted : September 13, 2018
Last Update Posted : July 17, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Palindromic Rheumatism, Wrist | Drug: Abatacept Injection Drug: hydroxycloroquina | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | National multi-center study, open, controlled and randomized |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA) |
Actual Study Start Date : | June 3, 2019 |
Actual Primary Completion Date : | June 30, 2022 |
Estimated Study Completion Date : | September 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: abatacept
abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
|
Drug: Abatacept Injection
Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
Other Name: ORENCIA |
Active Comparator: hydroxycloroquina
Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
|
Drug: hydroxycloroquina
oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months) |
- The main objective of this trial is to test abatacept efficacy [ Time Frame: At any time during the follow-up (up to 24 months) ]number of participants developed persistent arthritis fulfilling criteria of Rheumatoid Arthritis according to EULAR/ACR 2010 classification criteria persistent arthritis (RA criteria)
- Number of participants with treatment-related adverse events as asesed [ Time Frame: At any time during the follow-up (up to 24 months) ]Number of participants with treatment-related adverse events as asesed
- number of participants with titles positives on serum ACPA.(anti-CarP antibodies) [ Time Frame: At any time during the follow-up (up to 24 months) ]number of participants with titles positives on serum ACPA.(anti-CarP antibodies)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with PR according to Guerne and Weissman modified criteria (18) and with:
- Disease evolution > 3 months and < 24 months.
- ACPA positivity proven by ELISA test or chemiluminescence (CCP2) and/or Rheumatoid factor positivity (ELISA, nephelometry or chemiluminescence).
- Greater than 18 years of age.
Exclusion Criteria:
- Persistent arthritis: (involvement in one or more joints > 1 week).
- Criteria of other rheumatic diseases (RA, SLE, etc.).
- Evidence of radiographic damage (join erosions).
- Absence of ACPA or RF.
- Contraindication or intolerance to study drugs (abatacept or hydroxychloroquine).
- Steroid treatment one month before study entry.
- Previous antitrheumatic therapy with synthetic DMARDS (methotrexate, leflunomide, sulfasalazine, cyclosporine, antimalarials.) or biological DMARDs.
- Pregnant women or who want to be pregnant during the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03669367
Spain | |
Hospital Clinic i Provincial de Barcelona | |
Barcelona, Spain, 08036 |
Responsible Party: | Anna Cruceta, Project manager Clinical Trial Unit, Fundacion Clinic per a la Recerca Biomédica |
ClinicalTrials.gov Identifier: | NCT03669367 |
Other Study ID Numbers: |
PALABA 2017-004543-20 |
First Posted: | September 13, 2018 Key Record Dates |
Last Update Posted: | July 17, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Rheumatic Diseases Collagen Diseases Musculoskeletal Diseases Connective Tissue Diseases Abatacept Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents, Immunological Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |